UniProt Q91RS4
Q91RS4
Q91RS4 (UniProt Q91RS4): 12 experimental structures on GenesisL1. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q91RS4
- Experimental structures
- 12
- Predicted models
- 0
Structures
12 records of Q91RS4 in the MolNFT archive: 12 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1RTL | Crystal structure of HCV NS3 protease domain: NS4A peptide complex with covalently bound… | x-ray diffraction | A, B | — | — |
| 1RTL | Crystal structure of HCV NS3 protease domain: NS4A peptide complex with covalently bound… | x-ray diffraction | A, B | — | — |
| 2A4Q | HCV NS3 protease with NS4a peptide and a covalently bound macrocyclic ketoamide compound. | x-ray diffraction | A, C | — | — |
| 2A4Q | HCV NS3 protease with NS4A peptide and a covalently bound macrocyclic ketoamide compound. | x-ray diffraction | A, C | — | — |
| 2A4R | HCV NS3 Protease Domain with a Ketoamide Inhibitor Covalently bound. | x-ray diffraction | A, C | — | — |
| 2A4R | HCV NS3 protease domain with a ketoamide inhibitor covalently bound. | x-ray diffraction | A, C | — | — |
| 2F9U | HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with a P2 norborane | x-ray diffraction | A, C | — | — |
| 2F9U | HCV NS3 protease domain with NS4A peptide and a ketoamide inhibitor with a P2 norborane | x-ray diffraction | A | — | — |
| 2OBO | Structure of HEPATITIS C VIRAL NS3 protease domain complexed with NS4A peptide and ketoamide… | x-ray diffraction | A, C | — | — |
| 2OBO | Structure of hepatitis C viral NS3 protease domain complexed with NS4A peptide and ketoamide… | x-ray diffraction | A, C | — | — |
| 2XCN | Crystal structure of HCV NS3 protease with a boronate inhibitor | x-ray diffraction | A, B | — | — |
| 2XCN | Crystal structure of HCV NS3 protease with a boronate inhibitor | x-ray diffraction | A, B | — | — |
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.